Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K092355
    Date Cleared
    2009-10-29

    (86 days)

    Product Code
    Regulation Number
    866.3310
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The MONOLISA™ Anti-HAV EIA is an in vitro enzyme immunoassay kit intended for use in the qualitative detection of total antibodies (IgG and IgM) to hepatitis A virus (anti-HAV) in human (adult and pediatric) serum or plasma (EDTA, Heparin, Citrate, ACD). This kit can be used as an aid in the diagnosis of acute or past hepatitis A virus (HAV) infection or as an aid in the identification of HAV-susceptible individuals for vaccination. However, any diagnosis should take into consideration the patient's clinical history and symptoms, as well as serological data. The MONOLISA™ Anti-HAV EIA is intended for manual use and with the EVOLIS™ Automated Microplate System in the detection of total antibodies to hepatitis A virus.

    Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, and cord blood or neonatal specimens.

    Warning: This assay is not intended for screening blood or solid or soft tissue donors.

    Device Description

    The MONOLISA™ Anti-HAV EIA is an enzyme immunoassay (competitive assay format) for the detection of total antibodies to hepatitis A virus. In the assay procedure, patient specimens, a Calibrator and controls are incubated with HAV antigen in microwells that have been coated with mouse monoclonal anti-hepatitis A antibodies to HAV present in a specimen or control will complex with the HAV antigen reagent and with antibodies coated on the microwells. Excess sample and HAV Viral Antigen reagent are removed by a wash step. The Conjugate (containing horseradish peroxidase-labeled mouse monoclonal antibody to HAV) is subsequently added to the microwells and incubated. The Coniugate binds to the HAV antigen bound to the microwell, in the absence of antibodies to HAV from the specimen. Excess Conjuqate is removed by a wash step, and a TMB Chromogen/Substrate solution is added to the microwells and allowed to incubate. If a sample does not contain anti-HAV antibodies, the bound enzyme (HRP) causes the colorless tetramethylbenzidine (TMB) in the Chromogen solution to change to blue. The blue color turns vellow after the addition of a Stopping Solution. If a sample contains anti-HAV antibodies, the Chromogen/Substrate solution in the well remains colorless during the substrate incubation, and after the addition of the Stopping Solution. The color intensity is measured spectrophotometrically. Absorbance value readings for patient specimens are compared to the Cutoff value determined by the mean of the Calibrator absorbance values.

    The performance of the MONOLISA™ Anti-HAV EIA was evaluated in conjunction with the EVOLIS™ Automated Microplate System. The EVOLIS™ Automated Microplate System is a fully automated microplate analyzer that performs all functions necessary for the complete processing of microplate assays. Functions include: barcode scanning, sample pre-dilutions, sample and reagent dispensing, plate incubations, plate wash cycles, photometric measurement of completed assay plates and results evaluation. The analyzer instrument is controlled via the EVOLIS™ software, a Windows® 2000 application running on a separate dedicated PC. An operator loads the appropriate microplates, assay reagents, and patient and control samples, then selects assay parameters, loads sample information, initiates instrument processing, and generates result reports.

    AI/ML Overview

    Here's a summary of the acceptance criteria and study details based on the provided text, focusing on the performance of the MONOLISA™ Anti-HAV EIA when used with the EVOLIS™ Automated Microplate System.

    Acceptance Criteria and Device Performance

    The acceptance criteria for the MONOLISA™ Anti-HAV EIA with the EVOLIS™ Automated Microplate System are demonstrated by its substantial equivalence to the manual method (K063318). This equivalence is primarily shown through high percent agreement in comparative studies and acceptable precision and reproducibility.

    Acceptance Criteria (Implied from Predicate Equivalence)Reported Device Performance (MONOLISA™ Anti-HAV EIA on EVOLIS™)
    Correlation/Method Comparison
    Positive Percent Agreement (vs. Manual)98.8% (95% CI: 97.0 - 99.5%)
    Negative Percent Agreement (vs. Manual)97.4% (95% CI: 95.2 - 98.6%)
    Overall Percent Agreement (vs. Manual)98.1% (95% CI: 96.8 - 98.9%)
    Correlation/Method Comparison (Combination Plate)
    Positive Percent Agreement (vs. Manual)100% (95% CI: 97.7 - 100%)
    Negative Percent Agreement (vs. Manual)100% (95% CI: 97.6 - 100%)
    Overall Percent Agreement (vs. Manual)100% (95% CI: 98.8 - 100%)
    Precision (Within-Laboratory)Total %CV for various panel members ranged from 7.1% to 18.1% (e.g., Positive Control: 18.1%, Negative Control: 8.3%, Cutoff Control: 13.6%). Specific %CVs are provided for within-run, between-run, and between-day variability for 21-member panel and controls.
    Reproducibility (Multi-site)Total %CV for various panel members ranged from 5.9% to 8.8% across three sites (e.g., P1 Negative: 5.9%, P6 Positive: 7.8%, Positive Control: 8.8%). Specific %CVs are provided for within-run, between-day, and between-site variability.
    Pipetting AccuracyCV of ≤7.7% across the microwell plate.
    Carry-over (Pipetting & Washing)Verified that there is no carryover of residuals from one sample/well to another.

    Study Details

    1. Sample sizes used for the test set and the data provenance:

      • Main Correlation/Method Comparison: 688 retrospective samples. The country of origin is not specified.
      • Combination Plate Testing: 315 samples. The provenance (retrospective/prospective, country) is not specified, but they are compared to the "same samples tested manually."
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • The ground truth for the test set was established by the "manual method" of the MONOLISA™ Anti-HAV EIA (K063318). This is a previously cleared assay and not a consensus from human experts. Therefore, the concept of "number of experts" or their "qualifications" is not directly applicable here in the context of human interpretation of a diagnostic outcome. The "ground truth" is the result from the established and cleared manual assay.
    3. Adjudication method for the test set:

      • Not applicable as the ground truth is derived from a reference assay's output, not from human interpretation requiring adjudication. For borderline results in the main correlation study, specimens borderline with the reference assay and negative with EVOLIS™ were considered false negative for EVOLIS™, and specimens borderline with the reference assay and reactive with EVOLIS™ were considered false positive for EVOLIS™. This effectively defines how discrepancies were treated for agreement calculations.
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No MRMC comparative effectiveness study was performed. This device is an automated analyzer for an immunoassay, not an AI-assisted diagnostic tool that aids human readers in interpreting complex images or clinical data. The comparison is between an automated system and a manual laboratory method.
    5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

      • Yes, the performance data presented (correlation, precision, reproducibility) represents the standalone performance of the MONOLISA™ Anti-HAV EIA when run on the EVOLIS™ Automated Microplate System. The system performs all functions including reagent dispensing, incubation, washing, and photometric measurement, and results evaluation (based on optical density readings and cutoff values). The human operator's role is loading samples/reagents and initiating processing, not interpreting the primary assay output or forming a diagnosis from it directly.
    6. The type of ground truth used:

      • The ground truth (or reference method) was the MONOLISA™ Anti-HAV EIA tested manually, which is a previously FDA-cleared laboratory assay. This is a form of reference standard comparison against an established assay.
    7. The sample size for the training set:

      • The document does not specify a separate "training set" for the EVOLIS™ Automated Microplate System. Automated systems like this typically undergo a development and validation process during which algorithms (e.g., for robotic movements, optical density reading, cutoff calculations) are built and refined. The data presented here are for the performance validation of the final product. It's an assay system, not a machine learning model that requires a discrete "training set" in the conventional sense.
    8. How the ground truth for the training set was established:

      • Not applicable, as a distinct training set (in the machine learning sense) and its ground truth are not detailed in this submission. The ground truth for the performance validation was the previously cleared manual assay.
    Ask a Question

    Ask a specific question about this device

    K Number
    K063318
    Date Cleared
    2007-05-03

    (182 days)

    Product Code
    Regulation Number
    866.3310
    Reference & Predicate Devices
    N/A
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The MONOLISA™ Anti-HAV EIA is an in vitro enzyme immunoassay kit intended for use in the qualitative detection of total antibodies (IgG and IgM) to Hepatitis A Virus (anti-HAV) in human (adult and pediatric) serum or plasma (EDTA, Heparin, Citrate, ACD). This kit can be used as an aid in the diagnosis of acute or past Hepatitis A Virus (HAV) infection or as an aid in the identification of HAVsusceptible individuals for vaccination. However, any diagnosis should take into consideration the patient's clinical history and symptoms, as well as serological data.

    Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, and cord blood or neonatal specimens.

    WARNING : This assay is not intended for screening blood or solid or soft tissue donors.

    Device Description

    The MONOLISA™ Anti-HAV EIA is an enzyme immunoassay (competitive assay format) for the detection of total antibodies to Hepatitis A virus. In the assay procedure, patient specimens, a calibrator and controls are incubated with HAV antigen in microwells that have been coated with mouse monoclonal anti-Hepatitis A antibodies to HAV present in a specimen or control will complex with the HAV antigen reagent and with antibodies coated on the microwells. Excess sample and HAV Viral antigen reagent are removed by a wash step. The conjugate (containing horseradish peroxidase-labeled mouse monoclonal antibody to HAV) is subsequently added to the microwells and incubated. The conjuqate binds to the HAV antigen bound to the microwell in the absence of antibodies to HAV from the specimen. Excess conjugate is removed by a wash step, and a TMB Chromogen / Substrate solution is added to the microwells and allowed to incubate. If a sample does not contain anti-HAV antibodies, the bound enzyme (HRP) causes the colorless tetramethylbenzidine (TMB) in the Chromogen solution to change to blue. The blue color turns yellow after the addition of a Stopping Solution. If a sample contains anti-HAV antibodies, the Chromogen / Substrate Solution in the well remains colorless during the substrate incubation, and after the addition of the Stopping Solution. The color intensity is measured spectrophotometrically.

    Absorbance value readings for patient specimens are compared to the Cutoff value determined by the mean of the Calibrator absorbance values.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the MONOLISA™ Anti-HAV EIA, based on the provided document:

    Acceptance Criteria and Reported Device Performance

    CriteriaAcceptance Criteria (Implied by reported performance vs. comparative assay)Reported Device Performance (MONOLISA™ Anti-HAV EIA)
    Overall Positive Percent Agreement (PPA) with comparative assayNot explicitly stated, but generally expected to be very high (e.g., >95%)99.5% (931/936) with 95% CI (98.8% - 99.8%)
    Overall Negative Percent Agreement (NPA) with comparative assayNot explicitly stated, but generally expected to be very high (e.g., >95%)96.2% (378/393) with 95% CI (93.8% - 97.9%)
    PPA for US populationNot explicitly stated98.8% (237/240) with 95% CI (96.4% - 99.7%)
    NPA for US populationNot explicitly stated92.6% (151/163) with 95% CI (87.5% - 96.1%)
    PPA for European populationNot explicitly stated99.7% (610/612) with 95% CI (98.8% - 99.9%)
    NPA for European populationNot explicitly stated98.7% (227/230) with 95% CI (96.2% - 99.7%)
    PPA for Acute HAV InfectionNot explicitly stated100% (84/84) with 95% CI (96.5% - 100%)
    PPA for Pediatric SubjectsNot explicitly stated100% (29/29) with 95% CI (90.2% - 100%)
    NPA for Pediatric SubjectsNot explicitly stated96.8% (30/31) with 95% CI (83.3% - 99.9%)
    Seroconversion Panel Sensitivity (compared to comparative assay)Equivalent or more sensitiveEquivalent to or more sensitive in 6/6 panels.
    Device Precision (Within-run, Between-run, Between-day CV)CVs typically expected to be low (e.g.,
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1